New weekly injection for weight loss in overweight or obesity
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests a new weekly injection, efsubaglutide alfa (a GLP-1 drug), for helping people with overweight or obesity lose weight. It is for people who have not been able to lose weight with diet and exercise alone and do not have other serious health conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You are obese (BMI 30 or higher) or overweight (BMI 27-30) with at least one weight-related health condition.
- You have not had diabetes (type 1 or type 2).
- You have not taken weight-loss medications or certain other medicines in the past 3 months.
- You have not had weight-loss surgery or liposuction in the past year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an injection called efsubaglutide alfa to help obese teenagers lose weight. It requires following diet and exercise advice for at least 3 months before starting.
This trial tests a new injectable medicine (efsubaglutide alfa) given once every two weeks to help control blood sugar in people with Type 2 diabetes who have not taken diabetes medications for at least 8 weeks. It aims to see if it is safe and works better than a placebo.
This trial tests a new once-weekly injection called Ribupatide for weight loss in people with obesity who do not have diabetes. It compares the study drug to an existing medication (semaglutide) and a placebo to see how well it works and if it's safe.
This is an early-stage safety study testing a new medication called efsubaglutide in healthy adults. Researchers want to make sure it is safe and understand how the body processes it.
This study tests whether a weekly injection of semaglutide (the same drug in Wegovy and Ozempic) can help people with atrial fibrillation lose weight and improve their heart condition. It's for people with AF who also have obesity, and may or may not plan to have a heart procedure called catheter ablation.
This study tests a new weekly injection (BGM0504) to help people with obesity or overweight lose weight. It may be an option if you have not had success with diet and exercise alone and meet certain health criteria.
Hear when a new Obesity and Overweight trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.